Class-specific antibody response in acyclovir-treated and adenine arabinoside-treated patients with primary genital herpes simplex virus infection.
Herpes simplex virus (HSV) class-specific antibody responses after primary genital herpes infection were evaluated with an enzyme-linked immunosorbent assay (ELISA) in 16 patients treated with acyclovir (ACV), given orally, and 17 patients treated with adenine arabinoside (Ara-A), given topically. ACV significantly suppressed the levels of IgM, IgA, and IgG. In the ACV-treated patients, IgM and IgG were not detected in 4 of the 16 and in 1 of the 16 patients, respectively. We must take into account this suppressive effect of ACV on antibody responses, especially on the IgM response, when serodiagnosis of HSV infection is made.
Kawana
T
T
Department of Obstetrics and Gynecology, Tokyo University Branch Hospital, Japan.
Hashido
M
M
Koizumi
Y
Y
D000212:Acyclovir / Q000627:therapeutic use*; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000145:classification; D000918:Antibody Specificity; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000096:biosynthesis / Q000187:drug effects; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000187:drug effects; D007075:Immunoglobulin M / Q000096:biosynthesis / Q000187:drug effects; D008875:Middle Aged; D014740:Vidarabine / Q000627:therapeutic use*
D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D014740:Vidarabine; D000212:Acyclovir